Harrisvaccines has announced the U.S. Department of Agriculture licensure of the company’s swine flu vaccine, approved by the department’s Center for Veterinary Biologics for disease caused by swine influenza virus H3N2.


The vaccine is the first to be licensed by the USDA CVB that utilizes RNA Particle Technology. Dr. Kurt Kamrud, vice president of research and chief scientific officer at Harrisvaccines, led the company’s development and application of RNA Particle Technology — with the ultimate goal of producing a swine influenza vaccine that could be manufactured faster and safer than those produced using modified live or inactivated/killed virus technologies. This platform allows for the manufacture of vaccines without ever isolating a live virus from infected animals; only a gene from an infected animal is required to prepare vaccines in as little as four weeks.